Illustration photo about AstraZeneca’s Covid-19 vaccine
By Pushkala Aripaka
(Reuters) – A three-dose regimen of AstraZeneca’s Covid-19 vaccine is effective against the rapidly spreading Ômicron variant of the coronavirus, the drugmaker said on Thursday, citing data from an Oxford University laboratory study .
The study results, which are yet to be peer-reviewed and published in a medical journal, match those of competitors PFizer-BioNTech and Moderna, who also found that a third dose of their immunizers works against Ômicron.
AstraZeneca’s Vaxzevria vaccine study showed that after three doses of the immunizer, the levels of neutralization against Ômicron were broadly similar to those recorded against the Delta variant of the virus after two doses.
The company said the Oxford University researchers who conducted the study are independent of those who worked on the vaccine’s development with AstraZeneca.
Antibody levels against Ômicron after the booster dose were higher than antibodies in people who were infected and recovered naturally from Covid-19, the drugmaker added.
While initial data are positive for the company, AstraZeneca said on Tuesday that it is working in partnership with Oxford University to produce a tailored vaccine for Ômicron, as well as other vaccine makers.
(By Pushkala Aripaka in Bengaluru)
See too
+ Horoscope: check today’s forecast for your sign
+ Video: Driver leaves Tesla car on autopilot and sleeps on SP highway
+ Food stamps: understand what changes with new rules for benefit
+ See which were the most stolen cars in SP in 2021
+ Expedition identifies giant squid responsible for ship wreck in 2011
+ Everything you need to know before buying a crockpot
+ Discovered in Armenia most eastern aqueduct of the Roman Empire
+ US Agency warns: never wash raw chicken meat
+ Passenger attacks and pulls out two stewardess teeth
+ Aloe gel in the drink: see the benefits
+ Lemon-squeezing trick becomes a craze on social media
+ Lake Superior: the best freshwater wave in the world?
#AstraZeneca #booster #vaccine #works #Ômicron #laboratory #study #Oxford #ISTOÉ #MONEY